Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2014 FY- Text added to 2015 FY
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
New words:
ACA, AdaptImmune, adulteration, Aduro, atezolizumab, Augusta, AURI, aware, BARDA, began, Biotech, blended, BPCIA, Bristol, broaden, CAR, Children, circumstance, competitor, conceal, concealing, conception, congressional, constrain, conventional, corrected, correcting, correction, correctly, correspondingly, deadline, debilitating, dengue, departure, detention, EMA, enjoy, er, EU, falsifying, faster, FDCA, galactosyltransferase, Guinea, Idera, IIIA, imposition, Incyte, inside, interchangeable, irreversible, Israel, Johnson, juncture, justify, knowledge, mandated, Merrimack, misbranding, morbidity, mortality, mycoplasma, Nile, nonclinical, noncurrent, nonexclusive, notwithstanding, oncolytic, overstated, payer, pembrolizumab, possessed, precluded, preempted, qui, rarity, renegotiate, rom, routine, safeguarding, Sanofi, seizure, substance, switched, synthesizing, tam, Taxpayer, unbilled, underway, user, voluntary, waiver, whistleblower, whistleblowing, Zealand, Zika
Removed:
AB, abandonment, Abbott, acute, Affordability, Alimta, Altogether, Amgen, apportioned, asymptomatic, Avastin, BioNumerik, BioSante, Boehringer, castrate, cGCP, cisplatin, Codification, collectively, COMP, comparing, confer, dacarbazine, deducting, deficit, Dendreon, distinguished, DNA, dosed, drop, effected, effecting, Eli, equivalency, fluorouracil, formally, formulation, frame, globally, GmbH, greatest, grown, half, harvested, historically, HQJC, immunostimulatory, importance, imprisonment, Ingelheim, injected, Intron, inventor, ISO, KGaA, launched, lessor, licensure, Lilly, locoregional, logistical, lysate, managed, master, minimally, mycoplasm, nondeductible, nonvested, NovaRx, occupancy, Onyx, ordinarily, oversee, paclitaxel, payor, Pharma, PPACA, prevailing, profit, Proleukin, Provenge, purpose, recommend, refunded, Regeneron, resale, restated, retroactively, Sankyo, Science, Secretary, separately, shed, software, split, Squibb, stop, subscription, symptomatic, Synta, Tarceva, Taxotere, teach, tenant, unapproved, underwriter, underwriting, universe, vemurafenid, Vical, writing
Valuein 2014 FY filing- Value in 2015 FY filing
Original filings
Filing view